The predictive value of peripheral blood lymphocyte subsets for PD-1 therapy in esophageal cancer patients
CHEN Yi-xiang
CHEN Meng-yuan
ZHANG Hua-bin
LIN Xia-yi
QIAO Gui-bin
LAI Xiao-rong
LI Zi-jun
Abstract：Objective To explore the relationship between peripheral blood lymphocyte subsets and the prognosis of PD-1 therapy in esophageal cancer patients.Methods A total of 127 advanced esophageal cancer patients treated with immunotherapy at Guangdong Provincial People's Hospital were selected.Peripheral blood lymphocyte subsets were measured before and after treatment,and clinical data of the patients were collected.The relationship between lymphocyte subsets and the efficacy of PD-1 therapy was retrospectively analyzed.Results Before treatment,the proportion of CD3+cells(P＜0.05)and CD8+cells(P＜0.001)in the remission group(PR)was significantly lower than that in the non-remission group(PD+SD),while the CD4+/CD8+ratio(P＜0.01)and NK cell proportion(P＜0.05)were signifi-cantly higher than those in the non-remission group.After treatment,the proportion of peripheral blood CD8+cells in the remission group was significantly lower than that in the non-remission group(P＜0.05),while the proportion of CD19+cells was higher than that in the non-remission group(P＜0.05).The △CD19+(P＜0.05,the difference value of CD19+before and after treatment,the same below)and △CD19+CD5+(P＜0.05)in the remission group were signifi-cantly higher than those in the non-remission group.The combination of NK before treatment,CD8+before and after treatment,and three factors predicted the prognosis of esophageal cancer immunotherapy with the highest diagnostic effica-cy(AUC=0.840),the highest Youden index(0.625),and higher positive predictive value(0.812)and negative pre-dictive value(0.813).Conclusion A high CD4+/CD8+ratio,high proportion of NK cells,and low proportion of CD8+cells in the remission group indicate a good prognosis for immunotherapy.The combination of CD8+before and after treatment and NK before treatment has good diagnostic value for the efficacy of immunotherapy.
Keywords：esophageal cancerimmunotherapyPD-1 treatmentlymphocyte subpopulationsimmunotherapy prognosisprognostic evaluation of immunotherapy
Publication Date：2024-05-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 596-602 )